Pharmacogenomics of human UDP-glucuronosyltransferase enzymes

Pharmacogenomics Journal

Volumn 3, Issue 3, 2003, Pages 136-158

  Guillemette, Chantal ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Cancer susceptibility; Drug metabolism; Genetic polymorphism; Glucuronidation; SNP; UDP glucuronosyltransferase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANDROGEN; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ARGININE; ASPARAGINE; ASPARTIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; FLUOROURACIL; FOLINIC ACID; GENE PRODUCT; GLUCURONOSYLTRANSFERASE; GLUTAMIC ACID; IRINOTECAN; ISOENZYME; LEUCINE; LYSINE; METHYLDOPA; MORPHINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXAZEPAM; PHENYLALANINE; TRYPTOPHAN; TYROSINE; UNINDEXED DRUG; ZIDOVUDINE;

CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; DIARRHEA; DRUG METABOLISM; ENZYME POLYMORPHISM; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GILBERT DISEASE; GLUCURONIDATION; HUMAN; HYPERBILIRUBINEMIA; LUNG CANCER; NEUTROPENIA; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REVIEW;

ANIMALS; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACOGENETICS;

EID: 0037819284     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500171     Document Type: Review

References (205)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
2. Nowell SA, Massengill JS, Williams S, Radominska-Pandya A, Tephly TR, Cheng Z et al. Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5-b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. Carcinogenesis 1999; 20: 1107-1114.
3. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M et al. Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 1992; 98: 119-124.
4. Jin CJ, Miners JO, Burchell B, Mackenzie PI. The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. Carcinogenesis 1993; 14: 2637-2639.
5. Orzechowski A, Schrenk D, Bock-Hennig BS, Bock KW. Glucuronidation of carcinogenic arylamines and their N-hydroxy derivatives by rat and human phenol UDP-glucuronosyltransferase of the UGT1 gene complex. Carcinogenesis 1994; 15: 1549-1553.
6. Bock KW, Schirmer G. Species differences of glucuronidation and sulfation in relation to hepatocarcinogenesis. Arch Toxicol Suppl 1987; 10: 125-135.
7. 2-glucuronide conjugate of 2-hydroxyamino-MelQx in urine. Cancer Res 1999; 59: 5154-5159.
8. Vienneau DS, DeBoni U, Wells PG. Potential genoprotective role for UDP-glucuronosyltransferases in chemical carcinogenesis: initiation of micronuclei by benzo(a)pyrene and benzo(e)pyrene in UDP-glucuronosyltransferase-deficient cultured rat skin fibroblasts. Cancer Res 1995; 55: 1045-1051.
9. Kim PM, Wells PG. Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Cancer Res 1996; 56: 1526-1532.
10. Belanger A, Hum DW, Beaulieu M, Levesque E, Guillemette C, Tchernof A et al. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J Steroid Biochem Mol Biol 1998; 65: 301-310.
11. Hum DW, Belanger A, Levesque E, Barbier O, Beaulieu M, Albert C et al. Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 1999; 69: 413-423.
12. Liu J, Liu Y, Barter RA, Klaassen CD. Alteration of thyroid homeostasis by UDP-glucuronosyltransferase inducers in rats: a dose-response study. J Pharmacol Exp Ther 1995; 273: 977-985.
13. Dutton GJ. Glucuronidation of Drugs and other Compounds. CRC Press: Boca Raton, FL, 1980.
14. Jude AR, Little JM, Bull AW, Podgorski I, Radominska-Pandya A. 13-hydroxy- and 13-oxooctadecadienoic acids: novel substrates for human UDP-glucuronosyltransferases. Drug Metab Dispos 2001; 29: 652-655.
15. Weber WW. Pharmacogenetics. In: Motulsky, A.G., Bobrow, M., Harper, P.S., Schiver, C. (eds). Oxford Monographs on Medical Genetics. Oxford Universty Press: Oxford, 1997.
16. Inaba T, Nebert DW, Burchell B, Watkins PB, Goldstein JA, Bertilsson L et al. Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 1995; 73: 331-338.
17. Waring RH, Emery P. The genetic origin of responses to drugs. Br Med Bull 1995; 51: 449-461.
18. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13: 434-439.
19. Grant DM. Pharmacogenomics and the changing face of clinical pharmacology. Can J Clin Pharmacol 1999; 6: 131-132.
20. Herman RJ, Chaudhary A, Szakacs CB. Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. J Clin Pharmacol 1994; 34: 978-984.
21. Douglas AP, Savage RL, Rawlins MD. Paracetamol (acetaminophen) kinetics in patients with Gilber's syndrome. Eur J Clin Pharmacol 1978; 13: 209-212.
22. Carulli N, Ponz de Leon M, Mauro E, Manenti F, Ferrari A. Alteration of drug metabolism in Gilbert's syndrome. Gut 1976; 17: 581-587.
23. Patel M, Tang BK, Kalow W. Variability of acetaminophen metabolism in Caucasians and Orientals. Pharmacogenetics 1992; 2: 38-45.
24. Patel M, Tang BK, Grant DM, Kalow W. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics 1995; 5: 287-297.
25. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12: 102-107.
26. Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991; 51: 347-369.
27. Osborne NJ, Tonkin AL, Miners JO. Interethnic differences in drug glucuronidation: a comparison of paracetamol metabolism in Caucasians and Chinese. Br J Clin Pharmacol 1991; 32: 765-767.
28. Pacifici GM, Evangelisti L, Giuliani L, Metelli RM, Giordani R. Zidovudine glucuronidation in human liver: interindividual variability. Int J Clin Pharmacol Ther 1996; 34: 329-334.
29. Rajaonarison JF, Lacarelle B, De Sousa G, Catalin J, Rahmani R. In vitro glucuronidation of 3′-azido-3′-deoxythymidine by human liver. Role of UDP-glucuronosyltransferase 2 form. Drug Metab Dispos 1991; 19: 809-815.
30. Patel M. Genetic variability of an uridine-diphosphoglucuronosyltransferase: UGT2B7. Ph.D. Thesis, 1997.
31. Temellini A, Giuliani L, Pacifici GM. Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver. Br J Clin Pharmacol 1991; 31: 661-664.
32. Fischer D, Breyer-Pfaff U. Variability of diphenhydramine N-glucuronidation in healthy subjects. Eur J Drug Metab Pharmacokinet 1997; 22: 151-154.
33. Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 1997; 80: 91-96.
34. de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992; 102: 577-586.
35. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-854.
36. Macklon AF, Savage RL, Rawlins MD. Gilbert's syndrome and drug metabolism. Clin Pharmacokinet 1979; 4: 223-232.
37. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8: 1049-1051.
38. Burchell B, Coughtrie MW. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect 1997; 105 (Suppl 4): 739-747.
39. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit 1989; 11: 127-133.
40. Heinig R, Schaefer HG, Wensing G, Kuhlmann J. Pharmacokinetics, safety and tolerability of the orally administered receptor antagonist of cysteinyl-leukotrienes BAY × 7195 in single-dose escalation studies. Int J Clin Pharmacol Ther 1995; 33: 573-579.
41. Magdalou J, Herber R, Bidault R, Siest G. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 1992; 260: 1166-1173.
42. Shimoda K, Noguchi T, Ozeki Y, Morita S, Shibasaki M, Someya T et al. Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation. Neuropsycho-pharmacology 1995; 12: 323-333.
43. Robert J, David M, Granger C. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug. Cancer Chemother Pharmacol 1990; 27: 147-150.
44. Yue QY, Svensson JO, Alm C, Sjoqvist F, Sawe J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 1989; 28: 629-637.
45. Yue QY, Iselius L, Sawe J. Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism. Br J Clin Pharmacol 1997; 44: 239-244.
46. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679-685.
47. Bock KW, Wiltfang I, Blume R, Ullrich D, Bircher J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. Eur J Clin Pharmacol 1987; 31: 677-683.
48. Ullrich D, Sieg A, Blume R, Bock KW, Schroter W, Bircher J. Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest 1987; 17: 237-240.
49. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1 28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58: 353-356.
50. Barbier O, Albert C, Martineau I, Vallee M, High K, Labrie F et al. Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068), by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol 2001; 59: 636-645.
51. Liu HF, Vincent-Viry M, Galteau MM, Gueguen R, Magdalou J, Nicolas A et al. Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic? Eur J Clin Pharmacol 1991; 41: 153-159.
52. Little JM, Lester R, Kuipers F, Vonk R, Mackenzie PI, Drake RR et al. Variability of human hepatic UDP-glucuronosyltransferase activity. Acta Biochim Pol 1999; 46: 351-363.
53. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002; 181-182: 453-456.
54. Caldwell J, Davies S, Boote D, O'Gorman J. Interindividual variation in the sulfation and glucuronidation of paracetamol and salicylamide in human volunteers'. In: Mulder, GJ, Caldwell J, VanKempen, GMJ, Vonk, RJ. (eds). Sulphate Metabolism and Sulphate. Taylor and Francis: London, 1982, pp 251-261.
55. Burchell B, Coughtrie MW. UDP-glucuronosyltransferases. Pharmacol Ther 1989; 43: 261-289.
56. Vainio H, Elovaara E, Luukkanen L, Anttila S, Ulmanen I, Fournel-Gigleux S et al. Expression and co-induction of CYP1A1 and UGT1 6 in human lungs. Eur J Drug Metab Pharmacokinet 1995; 56: 47-48.
57. Benowitz NL, Perez-Stable E, Fong I, Jacob P. Differences in N-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for metabolism in congenital nonhemolytic jaundice. Clin Phamcol Ther 1998; 63: 148.
58. Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4: 209-218.
59. Sherwood RA, Marsden JT, Stein CA, Somasundaram S, Aitken C, Oxford JS et al. Intra-individual variation in serum AZT is not related to intestinal absorption or small intestinal inflammatory changes in human HIV-infected subjects. Antiviral Chem Chemother. 1997; 8: 327-332.
60. Bowman ED, Rothman N, Hackl C, Santella RM, Weston A. Interindividual variation in the levels of certain urinary polycyclic aromatic hydrocarbon metabolites following medicinal exposure to coal tar ointment. Biomarkers 1997; 2: 321-327.
61. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1 28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
62. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62: 608-617.
63. Ando M, Ando Y, Sekido Y, Shimokata K, Hasegawa Y. Genetic Polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 2002; 93: 591-597.
64. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
65. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10: 629-644.
66. Guillemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60: 950-956.
67. Guillemette C, De Vivo I, Hankinson SE, Haiman CA, Spiegelman D, Housman DE et al. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 2001; 10: 711-714.
68. Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 2001; 93: 1411-1418.
69. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 2001; 121: 1136-1144.
70. Strassburg CP, Vogel A, Kneip S, Tukey RH, Manns MP. Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 2002; 50: 851-856.
71. Gsur A, Preyer M, Haidinger G, Schatzl G, Madersbacher S, Marberger M et al. A polymorphism in the UDP-glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 497-498.
72. MacLeod SL, Nowell S, Plaxco J, Lang NP. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 2000; 7: 777-782.
73. Gestl SA, Green MD, Shearer DA, Frauenhoffer E, Tephly TR, Weisz J. Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. Am J Pathol 2002; 160: 1467-1479.
74. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26: 73-77.
75. Formelli F, Barua AB, Olson JA. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. FASEB J 1996; 10: 1014-1024.
76. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.
77. Zheng Z, Fang JL, Lazarus P. Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 2002; 30: 397-403.
78. Collier AC, Ganley NA, Tingle MD, Blumenstein M, Marvin KW, Paxton JW et al. UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol 2002; 63: 409-419.
79. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 2001; 33: 273-297.
80. King CD, Rios GR, Green MD, Tephly TR. UDP-glucuronosyltransferases. Curr Drug Metab 2000; 1: 143-161.
81. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255-269.
82. Monaghan G, Clarke DJ, Povey S, See CG, Boxer M, Burchell B. Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13. Genomics 1994; 23: 496-499.
83. Turgeon D, Carrier JS, Levesque E, Beatty BG, Belanger A, Hum DW. Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J Mol Biol 2000; 295: 489-504.
84. Beaulieu M, Levesque E, Tchernof A, Beatty BG, Belanger A, Hum DW. Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol 1997; 16: 1143-1154.
85. Owens IS, Ritter JK. Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Prog Nucleic Acid Res Mol Biol 1995; 51: 305-338.
86. Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 1992; 267: 3257-3261.
87. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11: 357-368.
88. Strassburg CP, Oldhafer K, Manns MP, Tukey RH. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 1997; 52: 212-220.
89. Strassburg CP, Mann MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. J Biol Chem 1998; 273: 8719-8726.
90. Mojarrabi B, Mackenzie PI. Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. Biochem Biophys Res Commun 1998; 247: 704-709.
91. Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J Biol Chem 1991; 266: 1043-1047.
92. Mojarrabi B, Butler R, Mackenzie PI. cDNA cloning and characterization of the human UDP glucuronosyltransferase, UGT1A3. Biochem Biophys Res Commun 1996; 225: 785-790.
93. Harding D, Fournel-Gigleux S, Jackson MR, Burchell B. Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc Natl Acad Sci USA 1988; 85: 8381-8385.
94. Wooster R, Sutherland L, Ebner T, Clarke D, Da Cruz e Silva O, Burchell B. Cloning and stable expression of a new member of the human liver phenol/bilirubin: UDP-glucuronosyltransferase cDNA family. Biochem J 1991; 278: 465-469.
95. Strassburg CP, Manns MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 1998; 273: 8719-8726.
96. Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7: 317-325.
97. Levesque E, Beaulieu M, Guillemette C, Hum DW, Belanger A. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology 1998; 139: 2375-2381.
98. Levesque E, Beaulieu M, Hum DW, Belanger A. Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1999; 9: 207-216.
99. Levesque E, Turgeon D, Carrier JS, Montminy V, Beaulieu M, Belanger A. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 2001; 40: 3869-3881.
100. Carrier JS, Turgeon D, Journault K, Hum DW, Belanger A. Isolation and characterization of the human UGT2B7 gene. Biochem Biophys Res Commun 2000; 272: 616-621.
101. Riedy M, Wang JY, Miller AP, Buckler A, Hall J, Guida M. Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmacogenetics 2000; 10: 251-260.
102. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001; 59: 405-414.
103. Jedlitschky G, Cassidy AJ, Sales M, Pratt N, Burchell B. Cloning and characterization of a novel human olfactory UDP-glucuronosyltransferase. Biochem J 1999; 340: 837-843.
104. Lazard D, Zupko K, Poria Y, Nef P, Lazarovits J, Horn S et al. Odorant signal termination by olfactory UDP glucuronosyl transferase. Nature 1991; 349: 790-793.
105. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31: 817-899.
106. Barbier O, Lapointe H, El Alfy M, Hum DW, Belanger A. Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry. J Clin Endocrinol Metab 2000; 85: 4819-4826.
107. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95: 8170-8174.
108. Bosma PJ, Goldhoon B, Bakker C. Presence of an additional TA in the TATAA box of B-UGT1 correlates with Gilbert's syndrome. Hepatology 1994; 20: 680.
109. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
110. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578-581.
111. Irwin M, Arias IML. Bilirubin glucuronide formation in vitro: demonstration of a defect in Gilbert's disease. Science 1957; 126: 563-564.
112. Israel JB, Arias IM. Inheritable disorders of bilirubin metabolism. Adv Intern Med 1976; 21: 77-96.
113. Black M, Billing BH. Hepatic bilirubin UDP-glucuronyl transferase activity in liver disease and Gilbert's syndrome. N Engl J Med 1969; 280: 1266-1271.
114. Burchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 1999; 14: 960-966.
115. Kaplan M. Genetic interactions in the pathogenesis of neonatal hyperbilirubinemia: Gilbert's syndrome and glucose-6-phosphate dehydrogenase deficiency. J Perinatol 2001; 21: S30-S34; discussion S35-S39.
116. Kadakol A, Sappal BS, Ghosh SS, Lowenheim M, Chowdhury A, Chowdhury S et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet 2001; 38: 244-249.
117. Monaghan G, McLellan A, McGeehan A, Li Volti S, Mollica F, Salemi I et al. Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. J Pediatr 1999; 134: 441-446.
118. Iolascon A, Faienza MF, Centra M, Storelli S, Zelante L, Savoia A. (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome. Haematologica 1999; 84: 106-109.
119. Yamamoto K, Sato H, Fujiyama Y, Doida Y, Bamba T. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1998; 1406: 267-273.
120. Akaba K, Kimura T, Sasaki A, Tanabe S, Ikegami T, Hashimoto M et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46: 21-26.
121. Maruo Y, Nishizawa K, Sato H, Doida Y, Shimada M. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 1999; 103: 1224-1227.
122. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65: 576-582.
123. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-4191.
124. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-3725.
125. Akaba K, Kimura T, Sasaki A, Tanabe S, Wakabayashi T, Hiroi M et al. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J Hum Genet 1999; 44: 22-25.
126. Senafi SB, Clarke DJ, Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 1994; 303: 233-240.
127. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997; 94: 10937-10942.
128. Haiman CA, Hankinson SE, Vivo ID, Guillemette C, Ishibe N, Hunter DJ et al. Polymorphisms in candidate breast cancer susceptibility genes and mammographic density. Breast Cancer Res Treatment 2003; 77:27-36.
129. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299: 998-1006.
130. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 1997; 7: 485-495.
131. Ebner T, Burchell B. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 1993; 21: 50-55.
132. Bock KW, Forster A, Gschaidmeier H, Bruck M, Munzel P, Schareck W et al. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem Pharmacol 1993; 45: 1809-1814.
133. Visser TJ, Kaptein E, Gijzel AL, de Herder WW, Ebner T, Burchell B. Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase isoenzymes. FEBS Lett 1993; 324: 358-360.
134. King CD, Rios GR, Assouline JA, Tephly TR. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch Biochem Biophys 1999; 365: 156-162.
135. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1 28 and UGT1A6 2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9: 341-349.
136. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001; 61: 3566-3569.
137. Girard H, Journault K, Guillemette C. Haplotypic structure of the carcinogen-metabolizing enzyme UGT1A7: nine polymorphic alleles (*1 through *9). Abstract #7485. ASPET, Experimental Biology 2003. San Diego, CA, USA, 2003.
138. Strassburg CP, Strassburg A, Nguyen N, Li Q, Manns MP, Tukey RH. Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J 1999; 338: 489-498.
139. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997; 6: 733-743.
140. Grove AD, Kessler FK, Metz RP, Ritter JK. Identification of a rat oltipraz-inducible UDP-glucuronosyltransferase (UGT1A7) with activity towards benzo(a)pyrene-7,8-dihydrodiol. J Biol Chem 1997; 272: 1621-1627.
141. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, Lazarus P. Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 2002; 62: 1978-1986.
142. Campbell H, Rudan I. Interpretation of genetic association studies in complex disease. Pharmacogenomics J 2002; 2: 349-360.
143. Guillemette C, Butler L, Duguay Y, Millikan R, Gagné J. Polymorphisms in UDP-glucuronosyltransferases as genetic factor modifying the risk of developing cancer. 18th European Workshop on Drug Metabolism. Valencia, Spain, 2002.
144. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001; 142: 778-787.
145. Radominska-Pandya A, Little JM, Pandya JT, Tephly TR, King CD, Barone GW et al. UDP-glucuronosyltransferases in human intestinal mucosa. Biochim Biophys Acta 1998; 1394: 199-208.
146. Radominska-Pandya A, Little JM, Czernik PJ. Human UDP-glucuronosyltransferase 2B7. Curr Drug Metab 2001; 2: 283-298.
147. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993; 264: 475-479.
148. Ritter JK, Sheen YY, Owens IS. Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3,4-catechol estrogens and estriol as primary substrates. J Biol Chem 1990; 265: 7900-7906.
149. Lampe JW, Bigler J, Bush AC, Potter JD. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev 2000; 9: 329-333.
150. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW et al. 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000; 28: 497-502.
151. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25: 1-4.
152. Coffman BL, Kearney WR, Green MD, Lowery RG, Tephly TR. Analysis of opioid binding to UDP-glucuronosyltransferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy. Mol Pharmacol 2001; 59: 1464-1469.
153. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL et al. Stereoselective conjugation of oxazepam by human UDP-Glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 2002; 30: 1257-1265.
154. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 2001; 29: 686-692.
155. Jin CJ, Mackenzie PI, Miners JO. The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 1997; 341: 207-211.
156. Albin N, Massaad L, Toussaint C, Mathieu MC, Morizet J, Parise O et al. Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res 1993; 53: 3541-3546.
157. Green MD, Oturu EM, Tephly TR. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab Dispos 1994; 22: 799-805.
158. Tomboc M, Barbier O, Hum D, Witchel S. UGT2B15 variants in hyperandrogenism: frequency of D85 and Y85 variants. Endocrine Society Meeting, Toronto, 2000.
159. Tomboc M, Hum D, Witchel S. Genotype analysis of UGT2B15 in children with prematurepubarche (PP) and adolescent girls with hyperandrogenism (HA). Endocrine Society Meeting, Denver, 2001.
160. Cheng Z, Radominska-Pandya A, Tephly TR. Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch Biochem Biophys 1998; 356: 301-305.
161. Cheng Z, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP-lucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 1999; 27: 1165-1170.
162. Huang YH, Galijatovic A, Nguyen N, Geske D, Beaton D, Green J et al. Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 2002; 12: 287-297.
163. Fournel-Gigleux S, Sutherland L, Sabolovic N, Burchell B, Siest G. Stable expression of two human UDP-glucuronosyltransferase cDNAs in V79 cell cultures. Mol Pharmacol 1991; 39: 177-183.
164. Ritter JK, Chen F, Sheen YY, Lubet RA, Owens IS. Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives. Biochemistry 1992; 31: 3409-3414.
165. Jin CJ, Miners JO, Lillywhite KJ, Mackenzie PI. cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun 1993; 194: 496-503.
166. Monaghan G, Burchell B, Boxer M. Structure of the human UGT2B4 gene encoding a bile acid UDP-glucuronosyltransferase. Mamm Genome 1997; 8: 692-694.
167. Coffman BL, Tephly TR, Irshaid YM, Green MD, Smith C, Jackson MR et al. Characterization and primary sequence of a human hepatic microsomal estriol UDPglucuronosyltransferase. Arch Biochem Biophys 1990; 281: 170-175.
168. Chen F, Ritter JK, Wang MG, McBride OW, Lubet RA, Owens IS. Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. Biochemistry 1993; 32: 10648-10657.
169. Jackson MR, McCarthy LR, Harding D, Wilson S, Coughtrie MW, Burchell B. Cloning of a human liver microsomal UDP-glucuronosyltransferase cDNA. Biochem J 1987; 242: 581-588.
170. Ritter JK, Yeatman MT, Ferreira P, Owens IS. Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyitransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J Clin Invest 1992; 90: 150-155.
171. Bosma PJ, Chowdhury JR, Huang TJ, Lahiri P, Elferink RP, Van Es HH et al. Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I. FASEB J 1992; 6: 2859-2863.
172. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Oude Elferink RP, Jansen PL et al. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 1992; 15: 941-947.
173. Aono S, Yamada Y, Keino H, Hanada N, Nakagawa T, Sasaoka Y et al. Identification of defect in the genes for bilirubin UDP-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun 1993; 197: 1239-1244.
174. Aono S, Adachi Y, Uyama E, Yamada Y, Keino H, Nanno T et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995; 345: 958-959.
175. Bosma PJ, Goldhoorn B, Oude Elferink RP, Sinaasappel M, Oostra BA, Jansen PL. A mutation in bilirubin uridine 5′-diphosphate-glucuronosyltransferase isoform 1 causing Crigler-Najjar syndrome type II. Gastroenterology 1993; 105: 216-220.
176. Moghrabi N, Clarke DJ, Boxer M, Burchell B. Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2. Genomics 1993; 18: 171-173.
177. Moghrabi N, Clarke DJ, Burchell B, Boxer M. Cosegregation of intragenic markers with a novel mutation that causes Crigier-Najjar syndrome type I: implication in carrier detection and prenatal diagnosis. Am J Hum Genet 1993; 53: 722-729.
178. Erps LT, Ritter JK, Hersh JH, Blossom D, Martin NC, Owens IS. Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro. J Clin Invest 1994; 93: 564-570.
179. Labrune P, Myara A, Hadchouel M, Ronchi F, Bernard O, Trivin F et al. Genetic heterogeneity of Crigler-Najjar syndrome type I: a study of 14 cases. Hum Genet 1994; 94: 693-697.
180. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994; 94: 2385-2391.
181. Ritter JK, Yeatman MT, Kaiser C, Gridelli B, Owens IS. A phenylalanine codon deletion at the UGT1 gene complex locus of a Crigler-Najjar type I patient generates a pH-sensitive bilirubin UDP-glucuronosyltransferase. J Biol Chem 1993; 268: 23573-23579.
182. Aono S, Yamada Y, Keino H, Sasaoka Y, Nakagawa T, Onishi S et al. A new type of defect in the gene for bilirubin uridine 5′-diphosphate-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type I. Pediatr Res 1994; 35: 629-632.
183. Koiwai O, Nishizawa M, Hasada K, Aono S, Adachi Y, Mamiya N et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet 1995; 4: 1183-1186.
184. Seppen J, Steenken E, Lindhout D, Bosma PJ, Elferink RP. A mutation which disrupts the hydrophobic core of the signal peptide of bilirubin UDP-glucuronosyltransferase, an endoplasmic reticulum membrane protein, causes Crigler-Najjar type II. FEBS Lett 1996; 390: 294-298.
185. Ciotti M, Obaray R, Martin MG, Owens IS. Genetic defects at the UGT1 locus associated with Crigler-Najjar type I disease, including a prenatal diagnosis. Am J Med Genet 1997; 68: 173-178.
186. Ciotti M, Chen F, Rubaltelli FF, Owens IS. Coding defect and a TATA box mutation at the bilirubin UDP-glucuronosyltransferase gene cause Crigler-Najjar type I disease. Biochim Blophys Acta 1998; 1407: 40-50.
187. Koiwai O, Aono S, Adachi Y, Kamisako T, Yasui Y, Nishizawa M et al. Crigler-Najjar syndrome type II is inherited both as a dominant and as a recessive trait. Hum Mol Genet 1996; 5: 645-647.
188. Chalasani N, Chowdhury NR, Chowdhury JR, Boyer TD. Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect. Gastroenterology 1997; 112: 2099-2103.
189. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000; 16: 297-306.
190. Gantla S, Bakker CT, Deocharan B, Thummala NR, Zweiner J, Sinaasappel M et al. Splice-site mutations: a novel genetic mechanism of Crigler-Najjar syndrome type 1. Am J Hum Genet 1998; 62: 585-592.
191. Huang CS, Luo GA, Huang MJ, Chen ES, Young TH, Chao YC. A novel compound heterozygous variation of the uridine-diphosphoglucuronosyl transferase 1A1 gene that causes Crigler-Najjar syndrome type II. Pharmacogenetics 2001; 11: 639-642.
192. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002; 292: 492-497.
193. Sappal BS, Ghosh SS, Shneider B, Kadakol A, Chowdhury JR, Chowdhury NR. A novel intronic mutation results in the use of a cryptic splice acceptor site within the coding region of UGT1A1, causing Crigler-Najjar syndrome type 1. Mol Genet Metab 2002; 75: 134-142.
194. Sutomo R, Laosombat V, Sadewa AH, Yokoyama N, Nakamura H, Matsuo M et al. Novel missense mutation of the UGT1A1 gene in Thai siblings with Gilbert's syndrome. Pediatr Int 2002; 44: 427-432.
195. Yamamoto K, Soeda Y, Kamisako T, Hosaka H, Fukano M, Sato H et al. Analysis of bilirubin uridine 5′-diphosphate (UDP)-glucuronosyltransferase gene mutations in seven patients with Crigler-Najjar syndrome type II. J Hum Genet 1998; 43: 111-114.
196. Herschel M, Beutler E. Low glucose-6-phosphate dehydrogenase enzyme activity level at the time of hemolysis in a male neonate with the African type of deficiency. Blood Cells Mol Dis 2001; 27: 918-923.
197. Passon RG, Howard TA, Zimmerman SA, Schultz WH, Ware RE. Influence of billrubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol 2001; 23: 448-451.
198. Sampietro M, Lupica L, Perrero L, Comino A, Martinez di Montemuros F, Cappellini MD et al. The expression of uridine diphosphate glucuronosyltransferase gene is a major determinant of bilirubin level in heterozygous beta-thalassaemia and in glucose-6-phosphate dehydrogenase deficiency. Br J Haematol 1997; 99: 437-439.
199. Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A, Beutler E. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci USA 1997; 94: 12128-12132.
200. Iolascon A, Miraglia del Giudice E, Perrotta S, Granatiero M, Zelante L, Gasparini P. Exclusion of three candidate genes as determinants of congenital dyserythropoietic anemia type II (CDA-II). Blood 1997; 90: 4197-4200.
201. Bancroft JD, Kreamer B, Gourley GR. Gilbert syndrome accelerates development of neonatal jaundice. J Pediatr 1998; 132: 656-660.
202. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999; 9: 591-599.
203. Monaghan G, Foster B, Jurima-Romet M, Hume R, Burchell B. UGT1 1 genotyping in a Canadian Inuit population. Pharmacogenetics 1997; 7: 153-156.
204. Fertrin KY, Goncalves MS, Saad ST, Costa FF. Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet 2002; 108: 117-119.
205. Biondi ML, Turri O, Dilillo D, Stival G, Guagnellini E. Contribution of the TATA-box genotype (Gilbert syndrome) to serum bilirubin concentrations in the Italian population. Clin Chem 1999; 45: 897-898.